Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties

Cytotechnology

Volumn 65, Issue 4, 2013, Pages 491-503

  Vu, Ngoc Bich ^a   Nguyen, Tam Thanh ^a   Tran, Long Cong Duy ^b   Do, Cong Dinh ^b   Nguyen, Bac Hoang ^b   Phan, Ngoc Kim ^a   Pham, Phuc Van ^a  

^a UNIVERSITY OF NATURAL SCIENCES   (Viet Nam)

^b UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY   (Viet Nam)

Author keywords

5 Fluorouracil; Antitumor drug resistance; Doxorubicin; Hepatic cancer stem cells; Hepatocellular carcinoma

Indexed keywords

ALPHA FETOPROTEIN; CD133 ANTIGEN; CD19 ANTIGEN; CD56 ANTIGEN; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; FLUOROURACIL; MICROSOMAL AMINOPEPTIDASE; OCTAMER TRANSCRIPTION FACTOR 4; RHODAMINE 123; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2;

ANIMAL EXPERIMENT; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; LIVER CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

EID: 84881161146     PISSN: 09209069     EISSN: 15730778     Source Type: Journal    
DOI: 10.1007/s10616-012-9511-9     Document Type: Article

References (103)

1. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, Iwakuma T (2010) CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70:4602-4612
2. Beier D, Röhrl S, Pillai DR, Schwarz S, Kunz-Schughart LA, Leukel P, Proescholdt M, Brawanski A, Bogdahn U, Trampe-Kieslich A, Giebel B, Wischhusen J, Reifenberger G, Hau P, Beier CP (2008) Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 68:5706-5715
3. Bourguignon LY, Peyrollier K, Xia W, Gilad E (2008) Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283:17635-17651
4. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, Wu M, Yin Z (2011) Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol 11:71
5. Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, Smith A (2003) Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell 5:643-655
6. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, Hung SC, Chang YL, Tsai ML, Lee YY, Ku HH, Chiou SH (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE 7:e2637
7. Cheng W, Liu T, Wan X, Gao Y, Wang H (2012) MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells. FEBS J 279:2047-2059
8. Cheung PF, Cheng CK, Wong NC, Ho JC, Yip CW, Lui VC, Cheung AN, Fan ST, Cheung ST (2011) Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. PLoS ONE 12:e28246
9. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H (2006) Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44:240-251
10. Chiou SH, Yu CC, Huang CY, Lin SC, Liu CJ, Tsai TH, Chou SH, Chien CS, Ku HH, Lo JF (2008) Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 13:4085-4095
11. Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A, Foglieni B, Spreafico M, Guerneri S, Baccarin M, Bertolini F, Rossi G, Mazzaferro V, Cadamuro M, Maggioni M, Agnelli L, Rebulla P, Prati D, Porretti L (2011) Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS ONE 6:e21369
12. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS (2010) Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 101:476-480
13. Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T, Cunningham D (1995) Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer 10:1594-1598
14. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC (2009) Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 44:1477-1486
15. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG (2010) NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28:5-16
16. Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, version 1.0. International agency for research on cancer CancerBase no. 5. IARC Press, Lyon
17. Ferrer Puchol MD, la Parra C, Esteban E, Vaño M, Forment M, Vera A, Cosín O (2011) Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma. Radiologia 53:246-253
18. Galli SJ, Zsebo KM, Geissler EN (1994) The kit ligand, stem cell factor. Adv Immunol 55:1-96
19. Geissler EN, Liao M, Brook JD (1991) Stem cell factor (SCF), a novel hematopoietic growth factor and ligand for c-kit tyrosine kinase receptor, maps on human chromosome 12 between 12q14.3 and 12qter. Somat Cell Mol Genet 17:207-214
20. Goodell MA (2001) Stem cell identification and sorting using the Hoeschst 33342 side population (SP). In: Current protocols in cytometry, unit 9.18
21. Guo Y, Liu S, Wang P, Zhao S, Wang F, Bing L, Zhang Y, Ling EA, Gao J, Hao A (2011) Expression profile of embryonic stem cell-associated genes Oct4, Sox2 and Nanog in human gliomas. Histopathology 4:763-775
22. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, Akita H, Takiuchi D, Hatano H (2010) CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120:3326-3339
23. Hochedlinger K, Yamada Y, Beard C, Jaenisch R (2005) Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 3:465-477
24. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H (2000) Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 32:228-232
25. Imrich S, Hachmeister M, Gires O (2012) EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 6:30-38
26. Jia Y, Liu H, Zhuang Q, Xu S, Yang Z, Li J, Lou J, Zhang W (2012) Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep 6:1865-1872
27. Kim M, Morshead CM (2003) Distinct populations of forebrain neural stem and progenitor cells can be isolated using side-population analysis. J Neurosci 23:10703-10709
28. Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, Nakajima A, Saito S (2012) Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol 18:1933-1939
29. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Hamamura K, Imai Y, Yoshida H, Shiina S, Omata M (2000) Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 32:1216-1223
30. Krieg A, Schulte Am EJ, Schmelzle M (2006) Stem cell factor levels do increase in patients subsequent to hepatectomy with the extent of parenchymal loss. Transplant Proc 38:3556-3558
31. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H (2001) Effects of long-term postoperative interferonalpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 134:963-967
32. Kumar V, Fausto N, Abbas A (eds) (2003) Robbins and Cotran pathologic basis of disease, 7th edn. Saunders, Philadelphia, USA, pp 914-917
33. Kumar V, Nelso F, Abul A (2004) Robbins and Cotran pathologic basis of disease, 7th edn. Saunders
34. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1998) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 3:479-483
35. Li CZ, Liu B, Wen ZQ, Li HY (2008) Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol (Praha) 6:180-186
36. Li WQ, Li YM, Tao BB, Lu YC, Hu GH, Liu HM, He J, Xu Y, Yu HY (2010) Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 10:HY27-HY30
37. Lin DY, Lin SM, Liaw YF (1997) Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 12:S319-S328
38. Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, Lu P, Jin F (2012) Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep 39:5875-5881
39. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408
40. Llovet JM, Bru C, Bruix J (1999) Prognsis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-338
41. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542-2556
42. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY (2008) Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6:1146-1153
43. Majka SM, Beutz MA, Hagen M, Izzo AA, Voelkel N, Helm KM (2005) Identification of novel resident pulmonary stem cells: form and function of the lung side population. Stem Cells 23:1073-1081
44. Mansuroglu T, Ramadori P, Dudás J, Malik I, Hammerich K, Füzesi L, Ramadori G (2009) Expression of stem cell factor and its receptor c-Kit during the development of intrahepatic cholangiocarcinoma. Lab Invest 89:562-574
45. Martin TN, Dargie H (2004) Silent right ventricular myocardial infarction: the Q wave never lies. Heart 90:1002
46. Maruyama S, Ando M, Watayo T (2003) Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer. Gan To Kagaku Ryoho 30:1635-1638
47. Mazzanti R, Giallombardo AL, Mini E, Nobili S, Neri B, Arena U, Pantaleo P, Fabbroni V, Ghilardi M, Gattai R, Bandettini L (2004) Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. Dig Liver Dis 36:278-285
48. Meeson AP, Hawke TJ, Graham S, Jiang N, Elterman J, Hutcheson K, Dimaio JM, Gallardo TD, Garry DJ (2004) Cellular and molecular regulation of skeletal muscle side population cells. Stem Cells 22:1305-1320
49. Meyer zu Schwabedissen HE, Kroemer HK (2011) In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol 201:325-371
50. Mikhail S, He AR (2011) Liver cancer stem cells. Int J Hepatol 2011:486954
51. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, Maruyama M, Maeda M, Yamanaka S (2003) The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 113:631-642
52. Moitra K, Lou H, Dean M (2011) Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin Pharmacol Ther 89:491-502
53. Montanaro F, Liadaki K, Volinski J, Flint A, Kunkel LM (2003) Skeletal muscle engraftment potential of adult mouse skin side population cells. Proc Natl Acad Sci USA 100:9336-9341
54. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma prevention study group. N Engl J Med 334:1561-1567
55. Namur J, Citron SJ, Sellers MT, Dupuis MH, Wassef M, Manfait M, Laurent A (2011) Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol 55:1332-1338
56. Niwa H, Miyazaki J, Smith AG (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 24:372-376
57. Park SH, Lee Y, Han SH, Kwon SY, Kwon OS, Kim SS, Kim JH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH (2006) Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 6:3
58. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH (2007) Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 110:129-137
59. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG (2005) Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res 65:6207-6219
60. Peng H, Qi J, Dong Z, Zhang JT (2010) Dynamic versus static ABCG2 inhibitors to sensitize drug resistant cancer cells. PLoS ONE 5:e15276
61. Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, Truong KD, Phan NK (2011) Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. J Transl Med 201:209
62. Pham PV, Vu NB, Duong TT, Nguyen TT, Truong NH, Phan NLC, Vuong TG, Pham VQ, Nguyen HM, Nguyen KT, Nguyen NT, Nguyen KG, Khat LT, Le DV, Truong KD, Phan NK (2012) Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatment. OncoTargets and Therapy 5:77-84
63. Phuc PV, Nhung TH, Loan DT, Chung DC, Ngoc PK (2011) Differentiating of banked human umbilical cord blood-derived mesenchymal stem cells into insulin-secreting cells. In Vitro Cell Dev Biol Anim 47:54-63
64. Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee BC, Hwang D, Yoon SK (2012) CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 315:129-137
65. Pilati P, Mocellin S, Bertazza L, Galdi F, Briarava M, Mammano E, Tessari E, Zavagno G, Nitti D (2012) Prognostic value of putative circulating cancer stem cells in patients undergoing hepatic resection for colorectal liver metastasis. Ann Surg Oncol 19:402-408
66. Prajapati HJ, Rafi S, El-Rayes BF, Kauh JS, Kooby DA, Kim HS (2012) Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. J Vasc Interv Radiol 23:1286-1293
67. Reber L, Da Silva CA, Frossard N (2006) Stem cell factor and its receptor c-kit as targets for inflammatory diseases. Eur J Pharmacol 533:327-340
68. Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A, Poggi A, Cappelli E, Zona G, Spaziante R, Corte G, Frosina G (2009) Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 7:383-392
69. Rountree CB, Ding W, Dang H, Vankirk C, Crooks GM (2011) Isolation of CD133+ liver stem cells for clonal expansion. J Vis Exp 56:3183
70. Sabisz M, Skladanowski A (2009) Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models. Cell Cycle 8:3208-3217
71. Sala M, Fuster J, Llovet JM, Navasa M, Sole M, Varela M, Pons F, Rimola A, Garcia-Valdecasas JC, Bru C, Bruix J (2004) High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 10:1294-1300
72. Shen Y, Cao D (2012) Hepatocellular carcinoma stem cells: origins and roles in hepatocarcinogenesis and disease progression. Front Biosci (Elite Ed) 4:1157-1169
73. Simpson K, Hogaboam CM, Kunkel SL (2003) Stem cell factor attenuates liver damage in a murine model of acetaminophen-induced hepatic injury. Lab Invest 83:199-206
74. Suenaga M (1988) 5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration. Gan No Rinsho 34:744-748
75. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820-824
76. Sun L, Hui AM, Su Q (2006) Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9:287-300
77. Tamada M, Nagano O, Tateyama S, Ohmura M, Yae T, Ishimoto T, Sugihara E, Onishi N, Yamamoto T, Yanagawa H, Suematsu M, Saya H (2012) Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells. Cancer Res 72:1438-1448
78. Terris B, Cavard C, Perret C (2010) EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 52:280-281
79. Thomas X, Cannas G (2010) Leukemia stem cells and new strategies to overcome resistance to therapy. Curr Stem Cell Res Ther 5:277-286
80. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS (2011) Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 12:570-594
81. Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY (2011) Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 40:621-628
82. Uchino K, Obi S, Tateishi R, Sato S, Kanda M, Sato T, Arano T, Enooku K, Goto E, Masuzaki R, Nakagawa H, Asaoka Y, Kondo Y, Yamashiki N, Goto T, Shiina S, Omata M, Yoshida H, Koike K (2012) Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol [Epub ahead of print]
83. Uhm JE, Park JO, Lee J, Park YS, Park SH, Yoo BC, Paik SW, Koh KC, Kang WK, Lim HY (2009) A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 63:929-935
84. Umemoto Y, Adachi Y, Ebisawa K (2005) The sural artery perforator flap for coverage of defects of the knee and tibia. Scand J Plast Reconstr Surg Hand Surg 39:209-212
85. Van Phuc P, Nhan PL, Nhung TH, Tam NT, Hoang NM, Tue VG, Thuy DT, Ngoc PK (2011) Downregulation of CD44 reduces doxorubicin resistance of CD44CD24 breast cancer cells. Onco Targets Ther 4:71-78
86. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474-481
87. Wang G, Wang Z, Sarkar FH, Wei W (2012) Targeting prostate cancer stem cells for cancer therapy. Discov Med 13:135-142
88. Welm B, Behbod F, Goodell MA, Rosen JM (2003) Isolation and characterization of functional mammary gland stem cells. Cell Prolif 36:17-32
89. World Health Organisation (2006) Cancer fact sheet, No. 207. February 2006
90. Wulf GG, Luo KL, Jackson KA, Brenner MK, Goodell MA (2003) Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. Haematologica 88:368-378
91. Xu XL, Xing BC, Han HB, Zhao W, Hu MH, Xu ZL, Li JY, Xie Y, Gu J, Wang Y, Zhang ZQ (2010) The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor. Carcinogenesis 31:167-174
92. Yamashita T (2012) Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy. Clin Drug Investig 32:15-23
93. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y (2008) EpCAM and alpha-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma. Cancer Res 68:1451-1461
94. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:1012-1024
95. Yan WW, Huang A, Li YG, Wang SS, Dai GH (2011) Expressions of CD34 and CD117 in human hepatocellular carcinomas and the clinical significance. Zhonghua Gan Zang Bing Za Zhi 19:588-593
96. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST (2008) Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13:153-166
97. Yasuda A, Sawai H, Takahashi H (2007) Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3 K/Akt pathway. Dig Dis Sci 52:2292-2300
98. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S, Gu J (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120:1444-1450
99. Yoon SK (2012) The biology of cancer stem cells and its clinical implication in hepatocellular carcinoma. Gut Liver 6:29-40
100. Yuan F, Zhou W, Zou C, Zhang ZHuH, Dai Z, Zhang Y (2010) Expression of Oct4 in HCC and modulation to wnt/β-catenin and TGF-β signal pathways. Mol Cell Biochem 343:155-162
101. Zhang L, Jiao M, Li L, Wu D, Wu K, Li X, Zhu G, Dang Q, Wang X, Hsieh JT, He D (2012) Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J Cancer Res Clin Oncol 138:675-686
102. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J, Li J (2010) Cancer stem/progenitor cells are highly enriched in CD133+ CD44+ population in hepatocellular carcinoma. Int J Cancer 126:2067-2078
103. Zou C, Yuan FJ, Zhou WB, Huang L, Wang J, Zhang YS (2009) Analysis on the expression of the stem cells related genes in hepatocellular carcinoma cell lines. Zhonghua Gan Zang Bing Za Zhi 17:599-602